NCT00827177 2014-01-24Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid TumorsArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Phase 1 Completed87 enrolled
NCT01069328 2013-11-13Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)BayerPhase 1 Completed33 enrolled
NCT00101413 2013-10-30BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)BayerPhase 2 Completed52 enrolled 11 charts
NCT00098254 2012-05-02BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung CancerNational Institutes of Health Clinical Center (CC)Phase 2 Completed37 enrolled 17 charts